ArticleJACC. Basic to translational science2021
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.
Article in JACC. Basic to translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Crizanlizumab for Treating COVID-19 Vasculopathy
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Endotheliopathy in Acute COVID-19 and Long COVID.International journal of molecular sciences · 2023Pooled it
- The acute and chronic implications of the COVID-19 virus on the cardiovascular system in adults: A systematic review.Progress in cardiovascular diseasesPooled it
- Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial.Circulation · 2023Trial
- Proteomic Insights into Venous Thromboembolism.Medical sciences (Basel, Switzerland) · 2026Review
- The Role of L-Arginine and Liposomal Vitamin C Supplementation as an Adjunct in Seasonal Respiratory Viral Infection Recovery.Advances in respiratory medicine · 2026Review
- P-Selectin and Platelet-Monocyte Interaction in Inflammation: Mechanisms, Hypothesis, and Open Questions.Journal of inflammation research · 2026Review
- COVID-19 in the Initiation and Progression of Atherosclerosis: Pathophysiology During and Beyond the Acute Phase.JACC. Advances · 2024Review
- Reduced Monocyte and Neutrophil Infiltration and Activation by P-Selectin/CD62P Inhibition Enhances Thrombus Resolution in Mice.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Breakthrough infections after COVID-19 vaccinations do not elicit platelet hyperactivation and are associated with high platelet-lymphocyte and low platelet-neutrophil aggregates.Research and practice in thrombosis and haemostasis · 2023Article
- The roles of P-selectin in cancer cachexia.Medical oncology (Northwood, London, England) · 2023Review
- P-Selectin de-ACTIVation in COVID-19: What Have We Learned?Circulation · 2023Article
- Uncoupling of platelet granule release and integrin activation suggests GPIIb/IIIa as a therapeutic target in COVID-19.Blood advances · 2023Article
- Platelets and SARS-CoV-2 During COVID-19: Immunity, Thrombosis, and Beyond.Circulation research · 2023Review
- Mechanisms of COVID-19 Associated Pulmonary Thrombosis: A Narrative Review.Biomedicines · 2023Review
- Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.Biomedicines · 2023Review
- Platelet-monocyte aggregates: molecular mediators of thromboinflammation.Frontiers in cardiovascular medicine · 2023Review
- Novel Strategies for the Treatment of COVID-19.Drugs in R&D · 2022Article
- An Overview of Repurposed Drugs for Potential COVID-19 Treatment.Antibiotics (Basel, Switzerland) · 2022Review
- COVID-19 Treatment-Current Status, Advances, and Gap.Pathogens (Basel, Switzerland) · 2022Review
- COVID-19 outcomes in sickle cell disease and sickle cell trait.Best practice & research. Clinical haematology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells. We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients with moderate COVID-19 were randomly assigned to receive either placebo or crizanlizumab, a P-selectin inhibitor, in a double-blind fashion. Crizanlizumab reduced P-selectin levels by 89%. Crizanlizumab increased D-dimer levels by 77% and decreased prothrombin fragment. There were no significant differences between crizanlizumab and placebo for clinical endpoints. Crizanlizumab was well tolerated. Crizanlizumab may induce thrombolysis in the setting of COVID-19. (Crizanlizumab for Treating COVID-19 Vasculopathy [CRITICAL]; NCT04435184).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.